查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1589531

直接作用抗病毒藥物市場：按類型、適應症、路線和分銷管道分類 - 全球預測 2025-2030

Direct-acting Antiviral Drug Market by Type (NS3/4A Protease, NS5A Protein, NS5B RNA-Dependent RNA polymerase), Indication (Hepatitis C Virus, HIV Infection/ AIDS, Influenza), Route, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年直接抗病毒藥物市場規模為107.1億美元，預計2024年將達到121.8億美元，複合年成長率為13.34%，2030年將達到257.6億美元，預計將達到1000萬美元。

直接作用抗病毒藥物（DAA）旨在直接抑制病毒複製，特別針對和抑制病毒酶功能。與傳統的基於干擾素的治療相比，這些藥物可提供更高的治癒率和更少的副作用，從而徹底改變丙型肝炎等病毒感染疾病的治療模式。對 DAA 的需求源於世界病毒感染疾病的負擔以及對有效、安全和快速治療方案的需求。其主要應用在醫療保健產業，針對醫院、診所、個別患者，也延伸到參與藥物開發的製藥公司。最終用途範圍廣泛，由於認知的提高和診斷方法的改進，在印度和中國等丙型肝炎高流行國家以及美國和歐洲等發達市場中，市場不斷擴大。

主要市場統計
基準年[2023] 107.1億美元
預測年份 [2024] 121.8億美元
預測年份 [2030] 257.6億美元
複合年成長率（%） 13.34%

主要的市場成長要素包括病毒感染率的增加、藥物配方的進步以及政府的支持措施。聯合治療、泛基因型藥物等創新蘊藏著市場拓展的潛在機會。抓住這些機會的建議包括投資更廣泛的抗病毒研發和策略聯盟。然而，高昂的治療成本、抗藥性突變和嚴格的監管要求等挑戰構成了重大限制。新興國家的價格敏感度和與藥品取得相關的挑戰進一步增加了市場障礙。然而，我們還有機會擴大獲取計劃、開發學名藥以及探索可有效對抗多種病毒基因型和感染疾病（例如流感和愛滋病毒）的藥物。

創新領域包括個人化醫療、利用人工智慧進行藥物發現、加強藥物傳輸系統。 DAA 中的微生物組調控和奈米技術等新興領域可能會開闢新的成長領域。 DAA 市場仍然競爭激烈，其特點是不斷的技術發展和監管審查。然而，策略性地利用科學進步並符合公共衛生需求的公司可能會在這個充滿活力的環境中取得成功。這些見解凸顯了 DAA 領域的成長和創新潛力，對於那些能夠成功應對其複雜性的公司來說。

市場動態：揭示快速發展的直接作用抗病毒市場的關鍵市場洞察

供需的動態交互作用正在改變直接作用抗病毒藥物市場。了解這些不斷變化的市場動態可以幫助組織做出明智的投資決策、改善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，並了解消費行為及其對製造成本的影響，並更清楚地了解對採購趨勢的影響。

  • 市場促進因素
    • 肝細胞癌和肝硬化的盛行率和發生率不斷增加
    • 增加新型直接抗病毒藥物的開發與上市
    • 提高新興國家的意識並改善醫療基礎設施
  • 市場限制因素
    • 直接作用抗病毒藥物高成本
  • 市場機會
    • 政府當局和社會衛生組織加強對直接抗病毒藥物的支持
    • 直接作用抗病毒藥物的可用性和組織之間的策略聯盟
  • 市場挑戰
    • 品牌直接作用抗病毒藥物專利到期

波特五力：駕馭直接作用抗病毒藥物市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解外部對直接作用抗病毒藥物市場的影響

外部宏觀環境因素在塑造直接抗病毒藥物市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解直接作用抗病毒藥物市場的競爭格局

對直接作用抗病毒藥物市場的詳細市場佔有率分析可以對供應商的績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示自己的競爭定位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV定位矩陣直接抗病毒藥物市場供應商績效評估

FPNV定位矩陣是評估直接作用抗病毒藥物市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議描繪了直接作用抗病毒藥物市場的成功之路

對於旨在加強在全球市場的影響力的公司來說，對直接作用抗病毒藥物市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 肝細胞癌和肝硬化的盛行率和發生率增加
      • 增加產品開發並推出新型直接作用抗病毒藥物
      • 提高新興國家的醫療意識並改善醫療基礎設施
    • 抑制因素
      • 直接作用抗病毒藥物高成本
    • 機會
      • 政府當局和社會醫療機構加強對直接抗病毒藥物的支持
      • 直接作用抗病毒藥物的可用性和組織之間的策略合作
    • 任務
      • 品牌直接作用抗病毒藥物專利到期
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章直接作用抗病毒藥物市場：依類型

  • NS3/4A蛋白酶
  • NS5A蛋白
  • NS5B RNA依賴性RNA聚合酵素

第7章 直接作用抗病毒藥物適應症市場

  • C型肝炎病毒
  • 愛滋病毒感染/愛滋病
  • 流感
  • 預防

第8章 直接作用抗病毒藥物市場：按途徑

  • 靜脈
  • 口服
  • 皮下的
  • 話題

第9章直接作用抗病毒藥物市場：按分銷管道

  • 醫院藥房
  • 網路藥局
  • 零售藥房

第10章 美洲直接作用抗病毒藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章 亞太直接作用抗病毒藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章 歐洲、中東和非洲直接作用抗病毒藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • Boehringer Ingelheim International GmbH.
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • EVERSANA
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Takeda Pharmaceutical Company Limited
  • Viatris Inc.
Product Code: MRR-032A67D91452

The Direct-acting Antiviral Drug Market was valued at USD 10.71 billion in 2023, expected to reach USD 12.18 billion in 2024, and is projected to grow at a CAGR of 13.34%, to USD 25.76 billion by 2030.

Direct-acting antiviral (DAA) drugs are designed to directly interfere with the replication of viruses, particularly targeting and inhibiting their enzymatic functions. These drugs have revolutionized the treatment landscape for viral infections like hepatitis C by offering high cure rates and fewer side effects compared to traditional interferon-based therapies. The necessity for DAAs arises from the global burden of viral infections and the need for effective, safe, and quick therapeutic options. Their primary application is in the healthcare industry, serving hospitals, clinics, and individual patients, while extending to pharmaceutical companies involved in drug development. The end-use scope is vast, including larger markets in countries with high incidences of hepatitis C, such as India and China, and expanding in developed markets like the U.S. and Europe due to growing awareness and improved diagnostics.

KEY MARKET STATISTICS
Base Year [2023] USD 10.71 billion
Estimated Year [2024] USD 12.18 billion
Forecast Year [2030] USD 25.76 billion
CAGR (%) 13.34%

Key market growth factors include increasing viral infection rates, advancements in drug formulations, and supportive government initiatives. Innovations such as combination therapies and pan-genotypic drugs hold potential opportunities for market expansion. Recommendations to seize these include investing in R&D and strategic collaborations for broader spectrum antiviral drugs. However, challenges such as high treatment costs, resistance mutations, and stringent regulatory requirements pose significant limitations. Price-sensitivity in emerging economies and challenges with drug accessibility further compound market hurdles. Nevertheless, opportunities lie in expanding access programs, developing generic versions, and exploring drugs effective against a broader range of viral genotypes and infections like influenza and HIV.

Innovative areas include personalized medicine, leveraging AI for drug discovery, and enhancing drug delivery systems. Emerging areas such as microbiome modulation and nanotechnology in DAAs could open new frontiers for growth. The DAA market remains highly competitive, characterized by continuous technological evolution and regulatory scrutiny. However, companies that strategically leverage scientific advancements and align with public health needs are likely to thrive in this dynamic environment. These insights highlight the potential for both growth and innovation within the DAA sector, for those who can navigate its complexities.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Direct-acting Antiviral Drug Market

The Direct-acting Antiviral Drug Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence and incidence of hepatocellular carcinoma and liver cirrhosis
    • Rising product development and launch of new direct-acting antiviral medicines
    • Growing awareness and improving healthcare infrastructure in emerging economies
  • Market Restraints
    • High cost of direct-acting antiviral drugs
  • Market Opportunities
    • Increasing support from government authorities & social healthcare associations for direct-acting antiviral drug
    • Availability of directly-acting antivirals medicines and strategic collaborations among organizations
  • Market Challenges
    • Patent expiration of branded direct-acting antiviral

Porter's Five Forces: A Strategic Tool for Navigating the Direct-acting Antiviral Drug Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Direct-acting Antiviral Drug Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Direct-acting Antiviral Drug Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Direct-acting Antiviral Drug Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Direct-acting Antiviral Drug Market

A detailed market share analysis in the Direct-acting Antiviral Drug Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Direct-acting Antiviral Drug Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Direct-acting Antiviral Drug Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Direct-acting Antiviral Drug Market

A strategic analysis of the Direct-acting Antiviral Drug Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Direct-acting Antiviral Drug Market, highlighting leading vendors and their innovative profiles. These include Boehringer Ingelheim International GmbH., Bristol-Myers Squibb Company, Cipla Limited, EVERSANA, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Novartis AG, Pfizer Inc., Takeda Pharmaceutical Company Limited, and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Direct-acting Antiviral Drug Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across NS3/4A Protease, NS5A Protein, and NS5B RNA-Dependent RNA polymerase.
  • Based on Indication, market is studied across Hepatitis C Virus, HIV Infection/ AIDS, Influenza, and Prophylaxis.
  • Based on Route, market is studied across Intravenous, Oral, Subcutaneous, and Topical.
  • Based on Distribution Channel, market is studied across Hospital Pharmacy, Online Drug Store, and Retail Pharmacy.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence and incidence of hepatocellular carcinoma and liver cirrhosis
      • 5.1.1.2. Rising product development and launch of new direct-acting antiviral medicines
      • 5.1.1.3. Growing awareness and improving healthcare infrastructure in emerging economies
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of direct-acting antiviral drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing support from government authorities & social healthcare associations for direct-acting antiviral drug
      • 5.1.3.2. Availability of directly-acting antivirals medicines and strategic collaborations among organizations
    • 5.1.4. Challenges
      • 5.1.4.1. Patent expiration of branded direct-acting antiviral
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Direct-acting Antiviral Drug Market, by Type

  • 6.1. Introduction
  • 6.2. NS3/4A Protease
  • 6.3. NS5A Protein
  • 6.4. NS5B RNA-Dependent RNA polymerase

7. Direct-acting Antiviral Drug Market, by Indication

  • 7.1. Introduction
  • 7.2. Hepatitis C Virus
  • 7.3. HIV Infection/ AIDS
  • 7.4. Influenza
  • 7.5. Prophylaxis

8. Direct-acting Antiviral Drug Market, by Route

  • 8.1. Introduction
  • 8.2. Intravenous
  • 8.3. Oral
  • 8.4. Subcutaneous
  • 8.5. Topical

9. Direct-acting Antiviral Drug Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Hospital Pharmacy
  • 9.3. Online Drug Store
  • 9.4. Retail Pharmacy

10. Americas Direct-acting Antiviral Drug Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Direct-acting Antiviral Drug Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Direct-acting Antiviral Drug Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Boehringer Ingelheim International GmbH.
  • 2. Bristol-Myers Squibb Company
  • 3. Cipla Limited
  • 4. EVERSANA
  • 5. F. Hoffmann-La Roche Ltd.
  • 6. Merck & Co., Inc.
  • 7. Novartis AG
  • 8. Pfizer Inc.
  • 9. Takeda Pharmaceutical Company Limited
  • 10. Viatris Inc.

LIST OF FIGURES

  • FIGURE 1. DIRECT-ACTING ANTIVIRAL DRUG MARKET RESEARCH PROCESS
  • FIGURE 2. DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. DIRECT-ACTING ANTIVIRAL DRUG MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. DIRECT-ACTING ANTIVIRAL DRUG MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. DIRECT-ACTING ANTIVIRAL DRUG MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. DIRECT-ACTING ANTIVIRAL DRUG MARKET DYNAMICS
  • TABLE 7. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY NS3/4A PROTEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY NS5A PROTEIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY NS5B RNA-DEPENDENT RNA POLYMERASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HEPATITIS C VIRUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HIV INFECTION/ AIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INFLUENZA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY PROPHYLAXIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ONLINE DRUG STORE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 37. BRAZIL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 40. CANADA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 41. CANADA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 44. MEXICO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 45. MEXICO DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 49. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 50. UNITED STATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 54. ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 55. ASIA-PACIFIC DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 58. AUSTRALIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 59. AUSTRALIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 62. CHINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 63. CHINA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 66. INDIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 67. INDIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 70. INDONESIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 71. INDONESIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 74. JAPAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 75. JAPAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 78. MALAYSIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 79. MALAYSIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 82. PHILIPPINES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 83. PHILIPPINES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 86. SINGAPORE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 87. SINGAPORE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH KOREA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH KOREA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 94. TAIWAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 95. TAIWAN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 98. THAILAND DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 99. THAILAND DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 102. VIETNAM DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 103. VIETNAM DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 107. EUROPE, MIDDLE EAST & AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 108. EUROPE, MIDDLE EAST & AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 111. DENMARK DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 112. DENMARK DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 115. EGYPT DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 116. EGYPT DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 119. FINLAND DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 120. FINLAND DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 123. FRANCE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 124. FRANCE DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 127. GERMANY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 128. GERMANY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 131. ISRAEL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 132. ISRAEL DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 135. ITALY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 136. ITALY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 139. NETHERLANDS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 140. NETHERLANDS DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 143. NIGERIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 144. NIGERIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 147. NORWAY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 148. NORWAY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 151. POLAND DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 152. POLAND DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 155. QATAR DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 156. QATAR DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 159. RUSSIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 160. RUSSIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 163. SAUDI ARABIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 164. SAUDI ARABIA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 167. SOUTH AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 168. SOUTH AFRICA DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 171. SPAIN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 172. SPAIN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 175. SWEDEN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 176. SWEDEN DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 179. SWITZERLAND DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 180. SWITZERLAND DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 183. TURKEY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 184. TURKEY DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED ARAB EMIRATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED ARAB EMIRATES DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 191. UNITED KINGDOM DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY ROUTE, 2018-2030 (USD MILLION)
  • TABLE 192. UNITED KINGDOM DIRECT-ACTING ANTIVIRAL DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 193. DIRECT-ACTING ANTIVIRAL DRUG MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 194. DIRECT-ACTING ANTIVIRAL DRUG MARKET, FPNV POSITIONING MATRIX, 2023